Alternatives to heart transplantation: Symposium of the "treatment of end-stage heart and lung failure" working group on October 22, 2005 in Munich

Thoracic and Cardiovascular Surgeon, Supplement

Volumn 55, Issue 2, 2007, Pages

  Struber M ^a   Lange, R ^b   Gummert, J F ^c   Beyersdorf, F ^d   Jurmann, M ^e   Schmid, C ^f   El Banayosy, A ^g   Hoppe, U C ^h   Steinbeck, G ⁱ   Reichenspurner, H ^j   Liebold, A ^k   Franz, W M ⁱ   Ruhparwar, A ^a   Schmoeckel, M ^l  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HEART CENTER HAMBURG   (Germany)

^k UNIVERSITY OF ROSTOCK   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FLUORODEOXYGLUCOSE; GLYCERYL TRINITRATE; LEVOSIMENDAN; NESIRITIDE; PHOSPHODIESTERASE INHIBITOR; TEZOSENTAN; TOLVAPTAN;

ARTIFICIAL HEART; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CARDIOMYOPLASTY; CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DEVICE; DRUG MECHANISM; DRUG MEGADOSE; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MITRAL VALVE REPLACEMENT; MYOBLAST; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; TISSUE ENGINEERING; TREATMENT OUTCOME; VENTRICULAR ASSIST DEVICE; XENOTRANSPLANTATION;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; HEART FAILURE; HEART, ARTIFICIAL; HEART-ASSIST DEVICES; HUMANS; MYOBLASTS; PACEMAKER, ARTIFICIAL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 34548744582     PISSN: 09464778     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-965414     Document Type: Conference Paper

References (113)

1. Hoppe et al. Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology - Heart and Circulation Research, compiled on behalf of the Clinical Cardiology Committee in cooperation with the Drug Committee of the German Physicians' Association. Z Kardiol 2001; 90: 218-237
2. Hunt SA et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82
3. Haas F et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30: 1693-1700
4. Appoo J et al. Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation 2004; 110 (Suppl 1): II13-II17
5. Trachiotis GD et al. Coronary artery bypass grafting in patients with advanced left ventricular dysfunction. Ann Thorac Surg 1998; 66: 1632-1639
6. Kleikamp G et al. Determinants of mid- and long-term results in patients after surgical revascularization for ischemic cardiomyopathy. Ann Thorac Surg 2004; 78: 1515-1516
7. DeRose JJ Jr et al. Preoperative prediction of long-term survival after coronary artery bypass grafting in patients with low left ventricular ejection fraction. J Thorac Cardiovasc Surg 2005; 129: 314-321
8. Yau TM et al. Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg 1999; 118: 1006-1013
9. Bolling SF. Mitral reconstruction in cardiomyopathy. J Heart Valve Dis 2002; 11 (Suppl 1): S26-S31
10. Seipelt RG et al. Downsizing of the mitral valve and coronary revascularization in severe ischemic mitral regurgitation results in reverse left ventricular and left atrial remodeling. Eur J Cardiothorac Surg 2001; 20: 270-275
11. Geidel S et al. Coronary artery bypass grafting in patients with advanced left ventricular dysfunction. Eur J Cardiothorac Surg 2005; 27: 1011-1016
12. Grossi EA et al. Ischemic mitral valve reconstruction and replacement: comparison of long-term survival and complications. J Thorac Cardiovasc Surg 2001; 122: 1107-1124
13. Haan CK et al. Selecting patients with mitral regurgitation and left ventricular dysfunction for isolated mitral valve surgery. Ann Thorac Surg 2004; 78: 820-825
14. Bishay ES et al. Mitral valve surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg 2000; 17: 213-221
15. Gummert JF et al. Mitral valve repair in patients with end stage cardiomyopathy: who benefits? Eur J Cardiothorac Surg 2003; 23: 1017-1022
16. Kass DA et al. Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation 1995; 91: 2314-2318
17. Patel HJ et al. Stabilization of chronic remodeling by asynchronous cardiomyoplasty in dilated cardiomyopathy: effects of a conditioned muscle wrap. Circulation 1997; 96: 3665-3671
18. Power JM et al. Passive ventricular constraint is a trigger for a significant degree of reverse remodeling in an experimental model of degenerative heart failure and dilated cardiomyopathy. Circulation 2000; 102 (Suppl): II501
19. Sabah HN et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 2003; 93: 1095-1101
20. Konertz WF et al. Passive containment and reverse remodeling by a novel textile cardiac support device. Circulation 2001; 104 (12 Suppl 1): 1270-1275
21. Aranda JM et al. Predictors of Hospital Length of Stay in a Surbical Approach to the Failing Heart: The ACORN Cardiac Support Device Randomized Trial Experience. 2004 HF Society of America poster presentation Sept 13, 2004
22. White HD et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51
23. Yamaguchi A et al. Left ventricular volume predicts postoperative course in patients with ischemic cardiomyopathy. Ann Thorac Surg 1998; 65: 434-438
24. Gaudron P et al. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their interrelation and prognostic impact. J Am Coll Cardiol. 2001; 38: 33-40
25. Di Donato M et al. Intermediate survival and predictors of death after surgical ventricular restoration. Semin Thorac Cardiovasc Surg 2001; 13: 468-475. Erratum in: Semin Thorac Cardiovasc Surg 2004; 16: 113
26. Athanasuleas CL et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 2005; 46: 1439-1445
27. Yamaguchi A et al. Left ventricular reconstruction benefits patients with dilated ischemic cardiomyopathy. Ann Thorac Surg 2005; 79: 456-461
28. Rose EA et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443
29. Stevenson LW et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004; 110: 975-981
30. Dembitsky WP et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg 2004; 78: 2123-2129
31. Healy AH et al. Improved Outcomes in Destination Therapy LvAD Patients: A Single Experience. 31st Abstract presented at the Annual Meeting of the Western Thoracic Surgical Association (WTSA), Victoria, British Columbia 2005
32. Pae WE et al. Initial European experience with the LionHeart(™) LVAS (left ventricular assist system) for destination therapy. 23rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Wien 2003. J Heart Lung Transplant 2003; 22 (1S): S83
33. Jurmann MJ et al. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg 2004; 25: 610-618
34. El-Banayosy et al. CardioWest total artificial heart: Bad Oeynhausen experience. Ann Thorac Surg 2005; 80: 548-552
35. Copeland JG et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351: 859-867
36. Shamim W et al. Incremental changes in QRS duration in serial ECGs overtime riidentify high-risk elderly patients with heart failure. Heart 2002; 88: 47-51
37. Faber L et al. Analysis of inter- and intraventricular asynchrony by tissue Doppler echocardiography. Z Kardiol 2003; 92: 994-1002
38. Anderson KP et al. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram. Prog Cardiovasc Dis 1996; 38: 463-488
39. Silverman ME et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75: 460-464
40. Schoeller R et al. First- or second-degree atrioventricular block as a risk factor in idiopathic dilated cardiomyopathy. Int J Cardiol 1993; 71: 720-726
41. Gottipaty VK. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic heart failure. (Abstract 847-4). J Am Coll Cardiol 1999; 33: 145A
42. Auricchio A et al. The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design, and endpoints of a prospecitve randomized multicenter study. Am J Cardiol 1999; 83: 130D-135D
43. Abraham WT et al. For the MIRACLE study group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853
44. Gras D et al. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. Pacing Clin Electrophysiol 1998; 21: 2249-2255
45. Leclerq C et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780-1787
46. Cleland JG et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
47. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure (the CArdiac REsynchronization - Heart Failure [CARE-HF] trial extension phase). Eur Heart J 2006; 27: 1928-1932
48. Bristow MR et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
49. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883
50. Bardy GH et al. Amiodarone or an implantable cardiodeverter- defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
51. Nieminen MS et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416
52. Follath F et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
53. Cleland JGF et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6: 501-508
54. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical statuts in acutely decompensated heart failure. Dallas, TX: American Heart Association Scientific Sessions, November 13-16, 2005
55. Mebazaa A. The SURVIVE trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Dallas, TX: American Heart Association Scientific Sessions, November 13-16, 2005
56. Colucci WS et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246-253
57. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540
58. Sackner-Bernstein JD et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-1905
59. Pouzet B et al. Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors? Circulation 2001; 104: 223-228
60. Jain M et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 104: 1920-1927
61. Ghostine S et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106: 131-136
62. Menasche P et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279-280
63. Menasche P et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2004; 41: 1078-1083
64. Hagege AA et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2004; 361: 491-492
65. Orlic D et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705
66. Murry CE et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668
67. Kajstura et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 2005; 96: 127-137
68. Tomita S et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002; 123: 1132-1140
69. Ma N et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. Cardiovasc Res 2005; 66: 45-54
70. Hagege AA et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2004; 361: 491-492
71. Beltrami AP et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-766
72. Urbanek K et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA 2003; 100: 10440-10450
73. Stamm C et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45-46
74. Stamm C et al. CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg 2004; 52: 152-158
75. Wollen KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-148
76. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918
77. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-1699
78. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294
79. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221
80. Assmus B, Honold J, Schachinger V et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-1232
81. Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-3017
82. Hofmann M, Wollen KC, Meyer GP et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-2202
83. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-121
84. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-1209
85. Penn MS. Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk. Lancet 2006; 367: 87-88
86. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. N Engl J Med 2006; 355: 1274-1277
87. Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344-10349
88. Ohtsuka M, Takano H, Zou Y et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 2004; 18: 851-853
89. Minaroguchi S, Takemura G, Chen XH et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postin-farction granulocyte colony-stimulating factor treatment. Circulation 2004; 109: 2572-2580
90. Harada M, Qin Y, Takano H et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305-311
91. Deindl E, Zaruba MM, Brunner S et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 2006; 20: 956-958
92. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436
93. Kuhlmann MT, Kirchhof P, Klocke R et al. G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med 2006; 203: 87-97
94. Valgimigli M, Rigolin GM, Cittanti C et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005; 26: 1838-1845
95. Ince H, Petzsch M, Kleine HD et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005; 112: 3097-3106
96. Engelmann MG, Theiss HD, Hennig-Theiss C et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48: 1712-1721
97. Ripa RS, Jorgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113: 1983-1992
98. Zohlnhofer D, Ott I, Mehilli J et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003-1010
99. Nir SG, David R, Zaruba M et al. Human embryonic stem cells for cardiovascular repair. Cardiovasc Res 2003; 58: 313-323
100. Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-414
101. Maitra A, Arking DE, Shivapurkar N et al. Genomic alterations in cultured human embryonic stem cells. Nat Genet 2005; 37: 1099-1103
102. Xiao YF, Min JY, Morgan JP. Immunosuppression and xenotransplantation of cells for cardiac repair. Ann Thorac Surg 2004; 77: 737-744
103. Zhang YM, Hartzeil C, Narlow M et al. Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. Circulation 2002; 106: 1294-1299
104. David R, Groebner M, Franz WM. Magnetic cell sorting purification of differentiated embryonic stem cells stably expressing truncated human CD4 as surface marker. Stem Cells 2005; 23: 477-482
105. Muller M, Fleischmann BK, Seibert S et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J 2000; 14: 2540-2548
106. Kofidis T et al. In vitro engineering of heart muscle: artificial myocardial tissue. J Thorac Cardiovasc Surg 2002; 124: 63-69
107. Ley R et al. A xenogeneic acellularized matrix for heart valve tissue engineering: in vivo study in a sheep model. Z Kardiol 2003; 92: 938-946
108. EBailey LL et al. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985; 254: 3321-3329
109. Schmoeckel M et al. Transplanting organs from pigs transgenic for a single human complement regulatory protein. Graft 2001; 4: 66-67
110. Brandl U et al. Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model. Xenotransplantation 2005; 12: 134-141
111. Kuwaki K et al. Heart transplantation in baboons using alpha 1, 3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31
112. McGregor CG et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851
113. Fishman JA et al. Xenotransplantation: infectious risk revisited. Am J Transplant 2004; 4: 1383-1390